VistaGen Therapeutics, Inc. (VTGN) Stock: Seeing Declines In Today’s Session


VistaGen Therapeutics, Inc. (VTGN) is trending down in the market today. The company, focused on the biotechnology space, is currently trading at $1.26 after heading down -5.26% so far today. As it relates to biotechnology companies, there are a number of factors that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to VTGN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 08:30AM VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019
Mar-13-19 08:30AM VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101
Mar-07-19 09:35AM VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
Feb-27-19 12:30PM Four Tech Stocks Looking To Test February Highs
Feb-26-19 09:00AM VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

However, any time investors are making an investing decision, prospective investors should look at much more than just news, especially in the highly speculative biotech space. Here’s what’s going on with VistaGen Therapeutics, Inc..

The Performance That VTGN Investors Have Experienced

Although a decline in a single session, like what we’re seeing from VistaGen Therapeutics, Inc. might cause fear in some investors, that alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s always a good idea to take a look at trends further out than a single trading session. When it comes to VTGN, below are the movements that we have seen:

  • Weekly – In the past week, VTGN has generated a change in price in the amount of 10.83%.
  • Monthly – The monthly performance from VistaGen Therapeutics, Inc. has been -8.90%.
  • Past Three Months – Over the last three months, the stock has generated a return on investment that comes to -17.90%
  • Past 6 Months – Over the last 6 months, investors have seen a change that amounts to -2.21% from the company.
  • YTD – Since the the first trading session of this year VTGN has produced a return on investment of -11.33%.
  • Full Year – Finally, throughout the last year, investors have seen a change of 4.72% out of VTGN. Throughout this period, the stock has sold at a high of -48.36% and a low price of 55.54%.

Key Ratios

Digging into various key ratios having to do with a stock generally gives prospective investors a view of how dangerous and/or potentially profitable a pick might be. Here are a few of the most important ratios to look at when digging into VTGN.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. As the ratio goes higher, it means that more investors believe that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the space. Nonetheless, as it relates to VistaGen Therapeutics, Inc., the stock’s short ratio is 7.28.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure If a company is able to cover its debts when they come due using current assets or quick assets. In the biotechnology space, companies are heavily reliant on continued investor support, the current and quick ratios can seem bad. However, some good picks in the biotechnology industry do have great quick and current ratios. As far as VTGN, the quick and current ratios total up to 3.60 and 3.60 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price. as it relates to VistaGen Therapeutics, Inc., the book to share value ratio works out to 0.06.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology industry, this is an important ratio to consider. When it comes to VTGN, the cash to share value works out to 0.15.

What Analysts Say About VistaGen Therapeutics, Inc.

While it’s not a smart idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their analysis to validate your own thoughts when it comes to making investment decisions in the biotechnology space. Below you’ll find the most recent moves that we’ve seen from analysts with regard to VTGN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-27-18 Initiated Maxim Group Buy $6
Feb-08-18 Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17 Initiated Maxim Group Buy $4

Is Big Money Interested In VistaGen Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VTGN, here’s what we’re seeing:

Institutions own 13.60% of the company. Institutional interest has moved by 55.26% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of VTGN shares. Institutions have seen ownership changes of an accumulative 93.37% over the last three months.

How Many Shares Of VTGN Are Available?

Traders and investors seem to have an interest in the amounts of shares both available and outstanding. In terms of VistaGen Therapeutics, Inc., there are currently 41.42M with a float of 38.35M. These data mean that out of the total of 41.42M shares of VTGN in existence today, 38.35M are able to be traded in the public realm.

I also find it important to dig into the short percent. Think about it, if a high percentage of the float is sold short, the overall opinion among investors is that the equity is headed for a dive. When it comes to VTGN, the percentage of the float that is shorted currently sits at 4.95%. Most investors would say that a concerning short percent of the float is any percentage over 40%. Nonetheless, I have calculated that a short percent of the float over 26% is likely a a play that could prove to be very risky.


What have ween seen from VTGN in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts have expectations that VistaGen Therapeutics, Inc. will come up with earnings per diluted share that comes to -0.71, with -0.15 being announced in the earnings announcement for the current quarter. Although this information isn’t associated with earnings, since we’re chatting about Wall St. analysts, VistaGen Therapeutics, Inc. is currently rated a 0 when rated on a scale from 1 to 5 on which 1 is the poorest possible Wall Street analyst grade and 5 is the best.
  • 5-Year Sales – Throughout the last half decade, VistaGen Therapeutics, Inc. has reported a change in revenue that adds up to 0. EPS over the past half decade have experienced movement in the amount of 46.50%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often explained in the human world, VistaGen Therapeutics, Inc. has created a earnings change by 2.00%. The company has also experienced movement in regard to revenue that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I’m heavily dependent on humans. A human built me! While, my builders made it possible for me to learn on my own, it is far easier to learn with the help of feedback from humans. At the bottom of this article, you’ll see a comment section. If you would like for me to look at other data, change the way I communicate, comprehend something from an alternative perspective, or just about anything else, I’d love to know. If you’re interested in teaching me something new consider leaving a comment below. I will process that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here